Search results for " INDUCTION"

showing 10 items of 526 documents

Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study

2005

Abstract Background. Almost 20% of patients with active Crohn's disease are refractory to conventional therapy. Infliximab is a treatment of proven efficacy in this group of patients and it is not clear which variables predict a good response. Aims. To evaluate the role of infliximab looking at the predictors of response in a large series of patients with Crohn's disease. Patients and methods. Five hundred and seventy-three patients with luminal refractory Crohn's disease (Crohn's Disease Activity Index (CDAI) > 220–400) (312 patients) or with fistulising disease (190 patients) or both of them (71 patients) were treated with a dose of 5 mg/kg in 12 Italian referral centres. The primary endp…

AdultMalemedicine.medical_specialtyFistulaPredictors of responseAge at diagnosisDiseaseGastroenterologyAntibodiesDose-Response RelationshipCrohn DiseaseGastrointestinal AgentsRefractoryInternal medicineMonoclonalmedicineHumansinfliximab.crohn's disease.Settore MED/12 - GastroenterologiaCrohn's diseaseDose-Response Relationship DrugHepatologybusiness.industryRemission InductionSmokingGastroenterologyAntibodies Monoclonalmedicine.diseaseCrohn's Disease Activity IndexInfliximabInfliximabSurgeryOpen studyCrohn's diseaseCrohn's disease; Infliximab; Predictors of response; Adult; Antibodies Monoclonal; Crohn Disease; Dose-Response Relationship Drug; Female; Fistula; Gastrointestinal Agents; Humans; Infliximab; Italy; Male; Multivariate Analysis; Remission Induction; SmokingItalyConcomitantMultivariate AnalysisFemaleCrohn's disease; Infliximab; Predictors of responseDrugbusinessmedicine.drugDigestive and Liver Disease
researchProduct

Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leu…

2015

Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m(2) intravenously on day 1), all-trans retinoic acid (45 mg/m(2) orally on days 4-6 and 15 mg/m(2) orally on days 7-28), high-dose cytarabine (3 g/m(2)/12 h intravenously on days 1-3) and mitoxantrone (12 mg/m(2) intravenously on days 2-3) in 93 patients aged 18-60 years refractory to one cycle of induction therapy. Primary end point of the study was response to therapy; secondary end points included evaluation of toxicities, in particular, rate of sinusoidal obstruction syndrome after allogeneic hematopoietic cell tr…

AdultMalemedicine.medical_specialtyGemtuzumab ozogamicinmedicine.medical_treatmentSalvage therapyTretinoinComorbidityKaplan-Meier EstimateAntibodies Monoclonal HumanizedGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansSalvage TherapyMitoxantroneChemotherapybusiness.industryRemission InductionCytarabineHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyArticlesMiddle Agedmedicine.diseaseGemtuzumab3. Good healthSurgeryTransplantationConsolidation ChemotherapyLeukemiaLeukemia Myeloid AcuteAminoglycosidesTreatment Outcome030220 oncology & carcinogenesisCytarabineFemaleMitoxantronebusiness030215 immunologymedicine.drugHaematologica
researchProduct

Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patie…

1998

Extensive pretreatment has been identified as a significant risk factor for failure of sufficient PBSC mobilization. From published data and our own experience we defined pretreatment variables which render patients at risk for not collecting at least 2.5 x 10(6) CD34-positive cells per kg bodyweight (BW). These variables were previous unsuccessful PBSC mobilization trial, previous large field radiotherapy, four or more cycles of myelosuppressive chemotherapy regimens, and combinations of extended field radiotherapy plus chemotherapy. Based on these inclusion criteria we treated 19 patients with disease-specific conventional-dose chemotherapy followed by sequential subcutaneous administrati…

AdultMalemedicine.medical_specialtyNeutropeniaFevermedicine.medical_treatmentPainSalvage therapyGastroenterologyTesticular NeoplasmsRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansMultiple myelomaTesticular cancerSalvage TherapyTransplantationMyelosuppressive ChemotherapyChemotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationDrug SynergismHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyHematopoietic Stem Cell MobilizationBlood Cell CountSeminomaSurgeryGranulocyte colony-stimulating factorLymphomaRegimenHematologic NeoplasmsFemaleInterleukin-3GerminomabusinessBone Marrow Transplantation
researchProduct

Twins born after transplantation of ovarian cortical tissue and oocyte vitrification

2009

Objective To present a combination of ovarian tissue and oocyte cryopreservation as an effective strategy for achieving pregnancy in a breast cancer patient. Design Case report. Setting Tertiary care university-affiliated hospital, tissue bank, and infertility clinic. Patient(s) A 36-year-old patient diagnosed with atypical medullar breast cancer and negative for estrogen, P, and HER2 receptors underwent ovarian tissue cryopreservation before receiving chemotherapy and radiotherapy. Intervention(s) Laparoscopic ovarian cortex extraction, ovarian tissue cryopreservation, ovarian tissue thawing and transplantation, controlled ovarian stimulation (COS), oocyte retrieval, vitrification and IVF,…

AdultMalemedicine.medical_specialtyOvarian Cortexmedicine.medical_treatmentTwinsOocyte RetrievalBreast NeoplasmsGestational AgeFertilization in VitroBiologyCryopreservationEmbryo Culture TechniquesAndrologyOvulation InductionPregnancymedicineHumansOvarian tissue cryopreservationFertility preservationCryopreservationGynecologyOvaryInfant NewbornObstetrics and GynecologyOocyte cryopreservationEmbryo TransferEmbryo transferTransplantationFertilityTreatment OutcomeReproductive MedicineOocytesFemaleOvulation inductionFertility and Sterility
researchProduct

Immune tolerance induction with moroctocog-alpha (Refacto/Refacto AF) in a population of Italian haemophilia A patients with high-titre inhibitors: D…

2019

Background: The appearance of inhibitors is the most serious complication in haemophilia A (HA) patients. The primary objective is their eradication. Up to date, immune tolerance induction (ITI) was the only therapeutic option to achieve this. Aim: To assess the efficacy of moroctocog-alpha as an ITI regimen in a population of HA patients with high-titre inhibitors. Methods: The REF.IT Registry is a retrospective-prospective study that collected data on all patients with HA and high-titre inhibitors treated with moroctocog-alpha as an ITI regimen at twelve Italian Haemophilia Centres. Results: We enrolled 27 patients, 85.2% were children. All patients were high responders, 88.9% had severe …

AdultMalemedicine.medical_specialtyPopulationHaemophilia AAlpha (ethology)030204 cardiovascular system & hematologyHaemophiliaHemophilia Ahaemophilia A with inhibitors; immune tolerance induction; moroctocog-alpha; poor-prognosis ITI patients; Adult; Child; Child Preschool; Factor VIII; Female; Hemophilia A; Humans; Immune Tolerance; Italy; Male; Prospective Studies; Retrospective Studies; Risk Factors; RegistriesImmune tolerance03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineImmune ToleranceMedicineHumansProspective StudiesRegistrieseducationHigh titrePreschoolChildGenetics (clinical)Retrospective Studiesimmune tolerance inductioneducation.field_of_studyFactor VIIIbusiness.industryHematologyGeneral Medicinehaemophilia A with inhibitormedicine.diseasepoor-prognosis ITI patientsRegimenItalymoroctocog-alphaChild PreschoolFemalebusinessComplicationhaemophilia A with inhibitors030215 immunologyHaemophilia : the official journal of the World Federation of HemophiliaREFERENCES
researchProduct

Female obesity impairs in vitro fertilization outcome without affecting embryo quality.

2008

Objective To compare embryo quality and reproductive outcome in our IVF program according to the women's body mass index (BMI). Design Retrospective study. Setting University-affiliated infertility clinic, between January 2001 and April 2007. Patient(s) Women undergoing a total of 6,500 IVF–intracytoplasmic sperm injection (ICSI) cycles. Intervention(s) Six thousand five hundred IVF-ICSI cycles were included and divided into four groups: lean ( 2 ; n=1,070; 16.5%); normal (20–24.9 kg/m 2 ; n=3,930; 60.5%); overweight (25–29.9 kg/m 2 ; n=1,081; 16.6%); and obese (≥30 kg/m 2 ; n=419; 6.4%). Main Outcome Measure(s) Comparison of embryo quality and reproductive outcome (implantation, pregnancy,…

AdultMalemedicine.medical_specialtyPregnancy Ratemedicine.medical_treatmentFertilization in VitroMiscarriageBody Mass IndexOvulation InductionThinnessPregnancymedicineHumansObesitySperm Injections IntracytoplasmicMetaphaseRetrospective StudiesGynecologyPregnancyIn vitro fertilisationObstetricsbusiness.industryBody WeightSmokingObstetrics and GynecologyOverweightmedicine.diseaseAbortion SpontaneousPregnancy rateTreatment OutcomeReproductive MedicineFertilizationembryonic structuresOocytesGestationFemalebusinessLive birthBody mass indexEmbryo qualityFertility and sterility
researchProduct

Day-3 embryo metabolomics in the spent culture media is altered in obese women undergoing in vitro fertilization

2015

Objective To determine whether the global metabolomic profile of the spent culture media (SCM) of day-3 embryos is different in obese and normoweight women undergoing in vitro fertilization (IVF). Design Prospective cohort analysis. Setting IVF clinic. Patient(s) Twenty-eight young, nonsmoking women with normoweight, nonsmoking male partners with mild/normal sperm factors undergoing a first IVF attempt for idiopathic infertility, tubal factor infertility, or failed ovulation induction: obese ovulatory women (n = 12); obese women with polycystic ovary syndrome (PCOS; n=4); normoweight ovulatory women (n = 12). Intervention(s) Fifty μl of SCM collected from two day-3 embryos of each cohort. M…

AdultMalemedicine.medical_specialtyProteomemedicine.medical_treatmentPhysiologyFertilization in VitroEmbryo Culture TechniquesHuman fertilizationInternal medicinemedicineHumansObesityProspective cohort studyIn vitro fertilisationbusiness.industryObstetrics and GynecologyEmbryoTubal factor infertilityEmbryo TransferEmbryo Mammalianmedicine.diseasePolycystic ovaryCulture MediaEndocrinologyGene Expression RegulationReproductive MedicineCohortMetabolomeFemaleOvulation inductionbusinessInfertility FemalePolycystic Ovary SyndromeFertility and Sterility
researchProduct

Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study.

2000

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) of unknown etiology frequently requiring long-term therapy for control of symptoms and prevention of relapse. Azathioprine (AZA) has been shown to be effective and safe in the treatment of chronic active UC. However, the alternatives to treatment with AZA are limited. Our aim was to compare the efficacy and safety of treatment with mycophenolate mofetil (MMF)/prednisolone versus standard immunosuppressive treatment with azathioprine (AZA)/prednisolone in patients with chronic active UC.The study was designed as an open comparison of MMF versus AZA. Twenty-four patients with active UC (Rachmilewitz scoreor =6 points) were randoml…

AdultMalemedicine.medical_specialtyRandomizationPrednisoloneAzathioprinePilot ProjectsMycophenolateGastroenterologyMycophenolic acidInternal medicineAzathioprineMedicineHumansColitisGlucocorticoidsAgedHepatologybusiness.industryChronic ActiveRemission InductionGastroenterologyMiddle AgedMycophenolic Acidmedicine.diseaseUlcerative colitisSurgeryChronic DiseasePrednisoloneColitis UlcerativeDrug Therapy CombinationFemalebusinessImmunosuppressive Agentsmedicine.drugThe American journal of gastroenterology
researchProduct

Ultra-long-distance running and the liver.

1990

During an ultra-long-distance race (1000 km in 20 days) the influence of running was examined on the enzymes aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AP), gamma-glutamyl-transferase (GGT), and glutamate dehydrogenase (GLDH) with regard to their release from the liver cells or their induction. Furthermore the liver synthetic capacity was assayed by measuring the enzyme activity of cholinesterase and the concentration of serum albumin during the race. Of the 110 participants, 55 finished the race and only the results of these runners were used in our study. AP increased continuously from day 0 (mean = 102 U/L) to day 19 (mean = 120 U/L). A fivefo…

AdultMalemedicine.medical_specialtySerum albuminPhysical Therapy Sports Therapy and Rehabilitationdigestive systemRunningInternal medicinemedicineHumansOrthopedics and Sports MedicineSerum AlbuminCholinesteraseAgedchemistry.chemical_classificationAnalysis of VariancebiologyLiver cellGlutamate dehydrogenaseAlbuminMiddle Ageddigestive system diseasesEnzyme assayOxygenEnzymeEndocrinologychemistryLiverEnzyme Inductionbiology.proteinPhysical EnduranceAlkaline phosphataseFemaleLiver CirculationInternational journal of sports medicine
researchProduct

Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial.

2011

Abstract Background Steroids, the mainstay of Crohn's disease treatment, have been associated with systemic side effects. Aim To evaluate the efficacy and tolerability of beclomethasone dipropionate for maintaining remission induced by a short course of systemic steroids in patients with Crohn's ileitis with or without right colonic involvement. Methods Patients (n = 84) with active Crohn's disease who achieved remission during a 2-week prednisone run-in period were randomised to receive beclomethasone dipropionate for 24 weeks or continue prednisone for a further 2 weeks followed by placebo for 22 weeks. The primary outcome was relapse rate (Crohn's Disease Activity Index score > 150 and a…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaRemissionKaplan-Meier EstimateBeclomethasone dipropionate Crohn's disease RemissionPlaceboGastroenterologyDrug Administration ScheduleMedication Adherencelaw.inventionDouble blindCrohn DiseaseDouble-Blind MethodRandomized controlled triallawPrednisoneInternal medicineSecondary PreventionmedicineHumansIleitisAdverse effectGlucocorticoidsAgedCrohn's diseaseHepatologybusiness.industryRemission InductionBeclomethasoneGastroenterologyBeclomethasone dipropionate Crohn's ileitis:.Middle Agedmedicine.diseaseSurgeryBeclomethasone dipropionateCrohn's diseaseTreatment OutcomeTolerabilityPrednisoneFemaleTablets Enteric-Coatedbusinessmedicine.drug
researchProduct